Apixaban Reduces Bleeding Risk Versus Rivaroxaban in Venous Thromboembolism

Direct oral anticoagulants have largely replaced vitamin K antagonists as the standard of care for managing acute venous thromboembolism, offering comparable efficacy without the need for routine coagulation monitoring [1]. While these medications generally demonstrate favorable safety profiles, the risk of hemorrhage remains a primary clinical concern, particularly in vulnerable populations such as patients with end-stage renal disease. In this group, apixaban reduces major bleeding rates compared to warfarin (relative risk 0.53, 95% confidence interval 0.45 to 0.64) [2]. Similarly, in adults aged 75 years and older, network meta-analyses show that apixaban significantly decreases bleeding risk compared to rivaroxaban (relative risk 0.28, 95% confidence interval 0.09 to 0.86) [3]. Broad analyses encompassing 76,641 patients further indicate that the risk of major bleeding is significantly lower with apixaban than with dabigatran (odds ratio 2.10, 95% confidence interval 1.07 to 4.12) and edoxaban (odds ratio 2.64, 95% confidence interval 1.36 to 5.15) [4]. However, clinicians have long lacked definitive, head-to-head randomized trial data directly comparing the safety of the two most commonly prescribed options. A new international trial now provides direct comparative evidence to help physicians navigate this daily prescribing dilemma.